Similarly, the depletion of VEGF-A by anti-VEGF-therapy leads to features of thrombotic microangiopathy with swollen endothelial cells and abnormal podocyte morphology10–12. The gene discussed is VEGFA; the disease is thrombotic microangiopathy.